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baseline in frequency volume chart variables, and post-void 
residual volume.
Results and limitations Compared with the controls, IM 
twice/day and IM nightly patients had a significantly lower 
night-time frequency (changes from baseline: 0.1 ± 0.8 in 
control, −0.6 ± 0.9 in IM twice/day, and −0.4 ± 1.0 in 
IM nightly, p = 0.5227, 0.0006 and 0.0143, respectively). 
The hours of undisturbed sleep and N-QOL score were sig-
nificantly improved in IM twice/day group, though not IM 
nightly group. Nocturnal urine volume was significantly 
reduced in IM nightly group, although total urine volume 
remained unchanged.
Conclusions A short half-life anticholinergic is suggested 
to be safe and effective as an add-on therapy for residual 
nocturia in patients with male LUTS receiving α1-blocker 
treatment. Anticholinergic administration nightly could 
reduce the nocturnal urine volume.
Abstract 
Purpose To evaluate the efficacy and safety of imidafena-
cin (IM), a novel short half-life anticholinergic, as add-
on therapy for male LUTS with nocturia and nocturnal 
polyuria.
Materials and methods This multicenter, prospec-
tive, randomized, open-labelled study was conducted and 
involved men who had frequency, urgency, and nocturia 
despite receiving a stable dose of α1-blocker for ≥1 month. 
Subjects were randomised to control (α1-blocker alone), 
IM twice/day (α1-blocker +0.1 mg imidafenacin twice 
daily), or IM nightly (α1-blocker plus 0.1 mg imidafenacin 
nightly) group; the treatment period was 8 weeks. Primary 
endpoints included improvements in night-time frequency 
and Nocturia Quality of Life Questionnaire (N-QOL) 
scores. Secondary endpoints included changes from the 
Trial identification: The clinical study design is posted at 
http://www.umin.ac.jp/ctr/ (Unique ID UMIN000002344).
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Introduction
Nocturia (night-time voiding)—defined as ‘the need to get 
up once or more times for nocturnal voids’ [1]—is the most 
common lower urinary tract symptom (LUTS), reportedly 
observed in up to 69 % of cases [2]. Since its prevalence 
increases with age [2, 3], it is more common in the elderly, 
and it greatly affects general health and quality of life 
[4–6]. Many individuals with nocturia, particularly elderly 
men, have other LUTS, including urinary frequency, weak 
stream, and urgency. In men, these symptoms are primarily 
attributed to benign prostatic hyperplasia (BPH). Therapy 
typically involves treatment for detrusor overactivity or 
bladder outlet obstruction. However, while either or both 
these aetiologies may underlie nocturia, therapy may fail 
because of an often overlooked component, namely noctur-
nal polyuria (NP) [7].
Treatment for voiding and/or storage symptoms sugges-
tive of BPH is now the initial choice for nocturia, and α1-
blockers, which target the dynamic component of prostatic 
obstruction, remain the most widely used pharmacological 
agents [8]. α1-Blockers for LUTS suggestive of BPH are 
expected to alleviate storage symptoms including nocturia. 
However, they are not adequately effective for nocturia-
related sleep disturbance. Anticholinergics with α1-blockers 
have shown statistical success in some groups, but the 
clinical significance of their effects is limited [9]. Anticho-
linergics reportedly improve overactive bladder (OAB) 
in nocturia by increasing bladder capacity but have no 
effect on NP [10]. We previously reported that imidafena-
cin decreased urine volume via suppression of C-fibres in 
the rat bladder [11] and clinically improved nocturia and 
reduced nocturnal urine volume [12]. However, the lat-
ter study was conducted mainly for female OAB patients. 
Thus, it remains unclear whether anticholinergics are effec-
tive for treating nocturia and NP, especially among men. 
Studies have reported that anticholinergics with α1-blockers 
are effective and safe for male LUTS [13–15]. However, 
these studies did not focus on nocturia and NP evaluated 
using urinary frequency volume charts (FVCs). Only lim-
ited data support the use of α1-blocker and anticholinergics; 
moreover, nocturia has rarely been used as a primary end-
point when studying these drug classes, and such studies 
have not consistently controlled for the effect of NP [16].
In this study, we investigated whether imidafenacin, a 
novel anticholinergic that has been marketed in Japan since 
2007 [17, 18], is effective for treating nocturia and NP.
Materials and methods
This multi-centre, randomised, 8-week study was con-
ducted at eight university hospitals in Japan between 
August 2009 and March 2011. The study, named the Good-
Night study, complied with the International Conference on 
Harmonization Good Clinical Practice Guideline and the 
Declaration of Helsinki. Further, the study protocol was 
approved by the review board of each hospital, and all sub-
jects provided written informed consent. The clinical study 
design is posted at http://www.umin.ac.jp/ctr/ (Unique ID: 
UMIN000002344).
Subject selection
Before the subjects were enrolled in this study, they under-
went behavioural therapy, including lifestyle guidance. Eli-
gible subjects included men with persistent nocturia (≥2 
voids/night) and LUTS including OAB symptoms [mean 
urinary frequency ≥8 times/24 h and ≥1 micturition-
related urgency episode/week, evaluated using the Overac-
tive Bladder Symptom Score (OABSS) [19]] who had been 
receiving a stable dose of an α1-blocker for ≥1 month. The 
International Prostate Symptom Score (IPSS)/IPSS-QOL 
was also evaluated. The exclusion criteria were as follows: 
post-void residual volume (PVR) ≥50 mL, complications 
that are contraindications for anticholinergics, high possi-
bility of prostate and bladder cancer, acute active urinary 
tract infection, indwelling or intermittent urethral cathe-
terisation, comorbidities that affect nocturia (sleep apnoea 
syndrome, restless leg syndrome, insomnia, etc.), hormone 
or 5-α-reductase inhibitor therapy that was started within 
the past 6 month, shift work and circadian rhythm disorder, 
irregular lifestyle, electrostimulation therapy or bladder 
training in the 10 days before the run-in period, contraindi-
cation for imidafenacin (primary angle-closure glaucoma, 
urinary retention, obstructive intestinal disease, paralytic 
ileus, gastrointestinal atony, and myasthenia gravis), and 
ineligibility as judged by the investigator in charge.
Study design
Eligible subjects were randomised to receive an 8-week 
continuous treatment with an α1-blocker alone (control), 
α1-blocker +0.1 mg imidafenacin twice daily (IM twice/
day), or α1-blocker plus 0.1 mg imidafenacin nightly (IM 
nightly). The subjects were randomly assigned to the three 
groups in a random sequence. Random assignment was 
performed by the central registration system of an inde-
pendent organisation, and age was used as a factor in the 
assignment. The α1-blockers were selected from common 
ones used in Japan (tamsulosin, naftopidil, and silodosin).
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Clinical assessments
The primary efficacy endpoints were improvements in 
night-time frequency as determined by the FVC, which 
was a 3-day bladder diary, and the Nocturia Quality of Life 
Questionnaire (N-QOL) score [20]. The N-QOL includes 
two domains, namely Sleep/Energy and Bother/Concern, 
and the total score and domain scores were calculated on 
a scale of 0–100, with 100 indicating ideal conditions. 
Secondary endpoints were other FVC variables, including 
hours of undisturbed sleep (HUS), 24-h micturition fre-
quency, daytime micturition frequency, nocturnal/daytime 
urine volume, nocturnal polyuria index (NPi; defined as 
nocturnal urine volume/24-h urine output), urine volume 
voided/void, PVR, OABSS, IPSS, IPSS-QOL, and at base-
line and at weeks 4 and 8. NP was diagnosed if the NPi 
was ≥33 %. Prostate volume and PVR were measured by 
ultrasound.
Adverse events (AEs) were classified by the investigator 
according to severity and relationship to the treatment.
Statistical analysis
Differences in FVC variables between treatment groups 
at baseline were evaluated using analysis of variance 
(ANOVA) at a significance level of 5 %; the N-QOL score 
and OABSS were evaluated using the two-sided Kruskal–
Wallis test. Intra- and intergroup numerical changes from 
baseline to 4 and 8 weeks were evaluated using paired and 
unpaired t tests, respectively (control vs. IM twice/day or 
IM nightly). Intra- and intergroup changes in categorical 
variables, including the N-QOL score and OABSS, from 
baseline to 4 and 8 weeks were evaluated using the Wil-
coxon and Mann–Whitney U tests, respectively (control vs. 
IM twice/day or IM nightly). The distribution of α1-blocker 
use during treatment and the mean duration of α1-blocker 
use before study entry were evaluated using Fisher’s exact 
test. Assessments of safety and tolerability were based on 
the findings for all patients who received at least one dose 
of the study medication. A two-sided significance level of 
5 % was applied for all statistical tests, except those con-
ducted on baseline characteristics. All analyses were per-
formed using SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Subject population
Patient disposition is summarised in Fig. 1. The base-
line demographic and clinical characteristics were simi-
lar among the three treatment groups (Table 1). From the 
FVCs, 78 % (101/130) of the subjects were found to have 
NP. The distribution of α1-blocker use did not differ signifi-
cantly among the three groups (Table 2), and 75 % (98/130) 
of the subjects used an α1-blocker for ≥3 month.
Frequency volume charts
Compared with the control group, those treated with imi-
dafenacin showed a significantly greater reduction in 
the nocturnal micturition (Table 3). Daytime frequency 
improved in the IM twice/day group but not in the IM 
nightly group (Table 3). The nocturnal urine volume in the 
control group remained unchanged throughout the study 
period, but imidafenacin treatment tended to reduce noc-
turnal urine production; in particular, 0.1 mg imidafenacin 
administered nightly reduced urine production significantly 
compared with that in the control group (Table 3). Further, 
in the IM nightly group, the 24-h urine volume remained 
unchanged, but NPi reduced significantly from the base-
line. HUS and urine volume voided/void at night signifi-
cantly improved in the IM twice/day group but not in the 
IM nightly group.
N-QOL score, OABSS, IPSS and IPSS-QOL
The total N-QOL score and subdomain scores at baseline 
were similar among the three treatment groups (Table 1). 
However, a marked increase was found in the N-QOL 
scores of the IM twice/day and IM nightly groups at 4 and 
8 weeks (Table 3). The OABSS significantly improved in 
all groups from the baseline to 8-week values (changes 
from baseline: −2.0 ± 0.4, control group; −2.9 ± 0.5, IM 
twice/day group; −2.2 ± 0.3, IM nightly group, not sig-
nificant by Kruskal–Wallis test). Similarly, the IPSS also 
improved in all groups compared with the baseline values 
(changes from baseline: −2.4 ± 0.8 in the control group, 
−3.4 ± 1.1 in the IM twice/day group, and −3.6 ± 0.7 in 
the IM nightly group, not significant by Kruskal–Wallis 
test). Further, the IPSS-QOL improved in all groups com-
pared with the baseline values (changes from baseline: 
−0.5 ± 0.2 in the control group; −1.3 ± 0.2 in the IM 
twice/day group; and −1.2 ± 0.2 in the IM nightly group, 
p = 0.013, <0.0001 and <0.0001, respectively). Compared 
with the control group, the other two groups showed sig-
nificantly improved IPSS-QOL scores (p = 0.0040 and 
0.0377, respectively).
Tolerability and safety
Treatment-emergent AEs were reported by no subjects in 
the control group, 18.5 % (10/54) of subjects in the IM 
twice/day group, and 25 % (12/48) of subjects in the IM 
nightly group (Table 4). Imidafenacin plus α1-blocker treat-
ment was not associated with an increased PVR (changes 
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from baseline: 3.9 mL in the control group, 6.8 mL in the 
IM twice/day group, and 7.5 mL in the IM nightly group). 
There were no reports of urinary retention.
Discussion
The Good-Night study is the first prospective randomised 
clinical trial that focused on nocturia, NP, and OAB 
symptoms, in order to evaluate the efficacy and safety of 
anticholinergics in male subjects on continued α1-blocker 
treatment. Additionally, this study showed the effect of 
anticholinergics on nocturia and NP in a real-life setting for 
the first time.
Nocturia has shown a poor clinical response to tradi-
tional OAB therapies, including anticholinergics [10]. 
Thus, other types of therapy will be needed to achieve a 
clinically significant reduction in nocturia. The use of the 
arginine–vasopressin analogue desmopressin in the treat-
ment of NP has been studied in certain groups of patients, 
because it is an antidiuretic. Low doses of desmopressin 
administered to elderly subjects were found to reduce NP 
[21]. However, desmopressin is associated with the risk of 
hyponatremia, which is the main potentially serious associ-
ated AE, and therefore, desmopressin is currently not rec-
ommended for patients >65 years old. Considering that the 
prevalence of nocturia and NP increases with age, the risk 
of AEs associated with some of the available medications 
warrants careful selection to optimise the therapeutic index.
A previous study on men with nocturia found an 83 % 
incidence of NP; 20 % of patients had NP alone, while 
63 % also had small nocturnal bladder capacity, bladder 
outlet obstruction, or sleep apnoea [22]. The current study 
seems to mirror real-life settings: 78 % of the subjects had 
Assessed for eligibility
n = 192
Excluded, n (%) 40 (20.1)
Criteria not met 32 (80.0)
Randomised for treatment Unwilling to participate 6 (14.2)
n = 152 Lost to follow-up 2 (25.8)
Control 1-blocker plus 1-blocker plus
( 1-blocker alone) 0.1 mg/day imidafenacin 0.1 mg/day imidafenacin nightly
n = 50 n = 54 n = 48
Discontinuation, n (%) Discontinuation, n (%) Discontinuation, n (%)
Related to study drug Related to study drug
Adverse event, 6 (11.1) Adverse event, 4 (8.3)
Not related to study drug Not related to study drug Not related to study drug
Subject defaulted, 2 (4.0) Subject defaulted, 1 (2.1)
Protocol deviations, 1 (2.0)
Other, 1 (2.0) Other, 3 (7.4) Other, 2 (4.2)
Completed n = 46 Completed n = 43 Completed n = 41
Fig. 1  Disposition of subjects assigned to the study treatments
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OAB with NP. Further, the distribution of α1-blocker use in 
the treatment period, mean duration of α1-blocker use, and 
types of α1-blockers used before study entry did not differ 
significantly among the groups. Thus, the results of the cur-
rent study were not influenced by the use of α1-blockers.
A well-known study known as the TIMES study showed 
the efficacy of combination therapy using α1-blockers and 
anticholinergics in male LUTS patients [13]. However, in 
TIMES study and other similar trials, the urine volume was 
not assessed. The objectives of the TIMES study thus dif-
fered from those of the Good-Night study, which focused 
on nocturia in male LUTS patients.
The primary endpoint in the Good-Night study, i.e. 
changes in night-time voiding frequency as determined 
using FVCs, was significantly reduced in the IM twice/day 
and IM nightly groups compared with that in the control 
group. This result is consistent with the findings of previ-
ous anticholinergic studies [13–15].
Unfortunately, in the present study, the baseline noc-
turia severity was lower in the control group than in the 
both study arms. Therefore, there may have been more 
room for improvement in the intervention groups than 
in the control group. However, no significant difference 
was found in the baseline OABSS among the groups, and 
OABSS nocturia score was similar among the groups 
(control group, 2.5 ± 0.5; IM twice/day, 2.7 ± 0.5; IM 
nightly group, 2.7. ± 0.5; p = 0.2290 by Kruskal–Wallis 
test, data not shown). Thus, it is unlikely that the differ-
ences in nocturia severity at baseline affected the results. 
In addition, the stratified analysis of patients with three or 
more nocturnal micturitions per night (baseline nocturnal 
micturition frequency: control group, 3.7 ± 0.3; IM twice/
day, 4.4 ± 0.3; IM nightly group, 3.9 ± 0.2; p = 0.1459 by 
ANOVA) indicated that patients treated with imidafenacin 
showed a significantly greater reduction in the frequency of 
nocturnal micturition compared to the control group [mean 
changes ± standard error (SE) from baseline to 8 weeks: 
control group, −0.1 ± 0.3; IM twice/day: −1.1 ± 0.2; 
IM nightly group, −0.7 ± 0.3, p = 07671, <0.0001 and 
0.0238, respectively].
The Good-Night study prospectively showed for the 
first time, to the best of our knowledge, that anticholiner-
gics could reduce nocturnal urine volume in male LUTS 
patients with residual OAB symptoms, which is a key 
finding. Our data support those of previous reports: one 
previous study showed that imidafenacin decreased urine 
volume through suppression of C-fibres in the rat bladder 
[11], and another showed that it clinically reduced noc-
turnal urine volume [12], although the latter study was 
mainly conducted on women with incontinence and NP. 
Imidafenacin has a unique pharmacokinetics profile: its 
Table 1  Patient demographics and background
All values were expressed as mean ± SD
BMI body mass index, PSA prostate-specific antigen, PVR post-void 
residual volume, OABSS Overactive Bladder Symptom Score, IPSS 
International Prostate Symptom Score, ANOVA analysis of variance
Control, α-blocker alone; IM twice/day, α-blocker plus 0.1 mg imi-
dafenacin twice daily; IM nightly, α-blocker plus 0.1 mg imidafena-
cin nightly
†
 p value: intergroup (control vs. 0.1 mg imidafenacin twice/day or 
0.1 mg imidafenacin nightly); ANOVA
‡
 p value: intergroup (control vs. 0.1 mg imidafenacin twice/day or 









Age (years) 73.3 ± 6.7 74.7 ± 6.2 74.7 ± 7.6 0.5376†
BMI (kg/m2) 23.1 ± 3.2 23.1 ± 4.0 22.8 ± 3.0 0.8956†
Prostate volume 
(mL)
31.7 ± 12.6 28.1 ± 11.3 31.4 ± 15.6 0.4437†
PSA (ng/mL) 2.6 ± 2.2 2.3 ± 2.5 2.4 ± 2.0 0.7707†
Comorbidity (%)
Hypertension 28.3 25.6 26.8 0.9689‡
Diabetes 4.3 14.0 14.6 0.2070‡
Renal disease 0.0 0.0 2.4 0.3154‡
Cerebrospinal 
disease
6.5 7.0 12.2 0.6750‡
PVR (mL) 18.9 ± 16.8 15.9 ± 13.5 23.4 ± 14.8 0.7978†
OABSS 7.84 ± 2.3 7.67 ± 2.3 7.79 ± 2.4 0.8612†
IPSS 15.5 ± 7.7 14.6 ± 7.5 15.4 ± 6.8 0.7927†
IPSS-QOL 4.24 ± 1.04 4.4 ± 1.16 4.25 ± 1.24 0.7915†
Table 2  α-Blocker use according to the enrolled subjects
All values were expressed as mean ± SD
Control, α-blocker alone; IM twice/day, α-blocker plus 0.1 mg imi-
dafenacin twice daily; IM nightly, α-blocker plus 0.1 mg imidafena-
cin nightly
†
 p value: intergroup (control vs. 0.1 mg imidafenacin twice/day or 









 Tamsulosin 13 (28.3 %) 9 (20.9 %) 15 (36.6 %) 0.6373
 Naftopidil 18 (39.1 %) 19 (44.2 %) 15 (36.6 %)
 Silodosin 15 (32.6 %) 15 (34.9 %) 11 (26.8 %)
Duration of α-blocker use before study entry [n (%)]
 ≥1 month 6 (13.0 %) 8 (18.6 %) 7 (17.1 %) 0.6887
 ≥2 months 4 (8.7 %) 5 (11.6 %) 2 (4.9 %)
 ≥3 months 6 (13.0 %) 5 (11.6 %) 2 (4.9 %)
 ≥6 months 30 (65.2 %) 25 (58.1 %) 30(73.2 %)
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half-life in blood is 2.9 h (it is referred to as a short half-
life anticholinergic), but its duration of receptor binding 
is longer in the bladder than in other organs (6–9 h in the 
bladder, 1–3 h in the submaxillary gland; no observation 
in the brain), and its metabolite has no pharmacologi-
cal activity [23, 24]. These properties differ from those 
of other anticholinergics. A possible explanation for how 
imidafenacin decreases the nocturnal urine volume is that 
it decreases the nocturnal urine volume directly by inhib-
iting bladder afferent nerves and/or indirectly by improv-
ing sleep disturbance. Elderly patients treated with sleeping 
pills have been shown to excrete smaller amounts of urine 
during the night [25], thus suggesting that sleep can result 
in reduced urine production.
In the current study, the IM twice/day group showed 
prolonged HUS, reduced night-time and daytime voiding 
frequency, and increased urine volume voided/void, as well 
as a tendency towards reduced NPi. These results are con-
sistent with previous findings [12].
Anticholinergics are commonly believed to have no 
effect on urine production; however, the IM nightly group 
showed significantly reduced urine production compared 
with the control group. During the period when the blood 
level of imidafenacin was high, urination was suppressed, 
particularly in the night-time, when urine production 
increases in patients with NP. In contrast, when the blood 
level of imidafenacin decreased in the daytime, urination 
was no longer suppressed, so the fluid balance over 24 h 
was normalised. Therefore, anticholinergics with a long 
half-life may be poor agents for reducing urine production, 
because their antidiuretic effect persists throughout the day. 
For instance, while tolterodine has shown an antidiuretic 
effect in rats [11], the effect of extended-release tolterodine 
on urine production has not been clinically proven.
Another primary endpoint was the N-QOL score. Using 
this score as an efficacy index, the Good-Night study found 
that anticholinergic add-on therapy was more effective 
than α1-blocker monotherapy in male LUTS patients with 
residual OAB symptoms. It clearly showed that the N-QOL 
scores in the IM twice/day and IM nightly groups at 4 and 
8 weeks were significantly increased from baseline and that 
the score in the IM twice/day group, but not the IM nightly 
group, was significantly higher than that in the control 
group. This improvement in HUS with imidafenacin may 
have important QOL and compliance benefits.
There have been concerns that the inhibitory effect of 
anticholinergics on detrusor muscle contraction could the-
oretically aggravate voiding difficulty, increase PVR, or 
cause urinary retention. However, in the Good-Night study, 
the PVR did not significantly increase from baseline to 
week 8 in any of the three groups.
The main study limitation is that this is a randomised 
but open-label, no-placebo and non-double-blinded study. 
To confirm the efficacy of a particular drug, a study should 
determine whether it is superior to a placebo and not infe-
rior to a pre-existing drug. However, previous phase three 
trials’ sub-analysis showed that imidafenacin 0.1 mg twice/
day significantly reduced nocturnal frequency and noctur-
nal urine volume compared with placebo group [12]. Fur-
ther research is required to draw a definitive conclusion 
regarding the reduction in nocturnal urine production by 
anticholinergics.
In conclusion, add-on therapy with a short half-life 
anticholinergic provides additional benefits for men with 
LUTS and nocturia who are undergoing α1-blocker therapy. 
Further, a short half-life anticholinergic may reduce noctur-
nal urine volume in addition to nocturnal frequency.
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Dry mouth 0 (0 %) 2 (3.7 %) 6 (12.5 %)
Constipation 0 (0 %) 3 (5.6 %) 1 (2.1 %)
Blurred vision 0 (0 %) 0 (0 %) 1 (2.1 %)
Anorexia 0 (0 %) 1 (1.9 %) 0 (0 %)
Insomnia 0 (0 %) 0 (0 %) 1 (2.1 %)
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Oedema in the limbs 0 (0 %) 0 (0 %) 1 (2.1 %)
Gastric ulcer 0 (0 %) 1 (1.9 %) 0 (0 %)
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Urinary AEs suggestive of 
AUR [n (%)]
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Mimihara General Hospital (Osaka); and Nanto Municipal Hospital 
(Toyama).
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